Previous close | 0.4100 |
Open | 0.4074 |
Bid | 0.3925 x 100 |
Ask | 0.0000 x 0 |
Day's range | 0.3880 - 0.4103 |
52-week range | 0.3880 - 6.4500 |
Volume | |
Avg. volume | 205,666 |
Market cap | 35.485M |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.3200 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.75 |
Apollomics’ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene Approval based on results from a randomized Phase 2/3 trial FOSTER CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers,
Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancerFOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American A
FOSTER CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif. Copies of the posters will be made available on the Apollomics website following the presentation at ir.a